What platinum/PARPi/DDR therapy should we give next?
Top 5 drug recommendations ranked by S/P/E framework. Mechanism-based matching with transparent scoring. Validated AUROC 0.70 (n=149).
Once you have CSI score, unlock drug recommendations and clinical trial matching. S/P/E framework (validated AUROC 0.70, n=149) ranks therapies by mechanism fit for DDR-targeted treatments.
The Problem: Generic Drug Ranking for DDR-Targeted Therapy
For patients with advanced, heavily pretreated cancer, clinicians need to know: ...
No Mechanism Understanding
Generic mutation lists don't explain why a DDR-targeted drug fits
No Transparent Reasoning
No clear scoring to understand why PARPi ranks higher than platinum for a specif
No Clinical Trial Matching
Missing mechanism-based trial matching means patients miss DDR-targeted combinat
The Solution: CSI-Powered Drug Recommendations with S/P/E Framework
Once you have CSI score, unlock drug recommendations and clinical trial matching
S/P/E Framework
Sequence (30%) + Pathway (40%) + Evidence (30%) for comprehensive drug ranking
Confidence & Tiers
Evidence tiers (Supported/Consider/Insufficient) with confidence scores and badg
Insights Integration
4 insights chips provide confidence lifts when biological signals align
How Level 2 Works
Four steps to unlock this capability
Take CSI Score from Level 1
CSI Score (0-100) with 6-month PFS probability
Add Genomic Test Results (NGS)
Genomic profile ready for S/P/E calculation
Calculate S/P/E Scores
S/P/E scores for each DDR-targeted drug
Rank Drugs and Match Clinical Trials
Top 5 ranked drugs + Clinical trial matches
CSI in Action: Continuous Monitoring
See how CSI updates automatically as tumor evolves. Track chemosensitivity across treatment lines with real-time alerts when CSI drops below threshold.
Level 2: Genomic Monitoring
Add genomic testing to detect resistance mutations and find clinical trials
CSI Continuous Monitoring
Track CSI score updates as tumor evolves. Never miss a chemosensitivity change. • Patient AK
ChemoSensitivity Index
3/4/2026
Tumor Marker
2/26/2026
CT Scans
2/12/2026
Liquid Biopsy
3/4/2026
Clinical Trials
3/3/2026
Active Alerts & Insights
3 Active(1 locked at Level 3)CSI Score Decreased
Your CSI score dropped, meaning chemo is becoming less effective
CA-125 Plateau
Your CA-125 stopped declining and is staying flat
New Trial Match
A clinical trial that matches your specific tumor biology just opened
Next: Level 3 - Resistance Prediction
Get early warnings 3-6 weeks before imaging shows treatment failure
Level 2 Performance Metrics
Validated performance for this capability
Validation Status
Validated performance for this capability
Ready for Level 3?
Predict when chemo might stop working and when to retest. Post-treatment pathway profiling captures tumor evolution after treatment.